Insulet Corp is a medical device company based in Billerica, Massachusetts. The company develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.
Hedge Funds Were Selling Insulet Corporation (PODD) Before The Coronavirus
Mar 17, 2020 @ 19:17
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]...
Insulet’s Omnipod DASH™ System Voted 2020 Product of the Year in Health Systems Category by 40,000 U.S. Consumers
Mar 05, 2020 @ 11:00
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® DASH Insulin Management System (Omnipod DASH™ System), announced today that the Company’s Omnipod DASH™ System has been named the 2020 Product of the Year in the Health...
Insulet Provides Update on Pivotal Study of Omnipod Horizon™
Mar 02, 2020 @ 11:00
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that it plans to pause the pivotal study of the Omnipod Horizon™ Automated Glucose Control System to correct a software anomaly...
Here's how local companies are reacting to the coronavirus
Feb 28, 2020 @ 19:26
While many Massachusetts companies are taking a wait-and-see approach to see if the coronavirus spreads in the Bay State, many are taking proactive measures to protect employees, maintain supply chains or get ready for major delays....
Insulet (PODD) delivered earnings and revenue surprises of -11.11% and 5.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...
Diabetes Devices Outlet Tumbles On Mixed Report As Earnings Lag
Feb 25, 2020 @ 21:35
Diabetes treatment player Insulet reported a mixed fourth quarter as adjusted earnings of 8 cents per share lagged expectations, though $209.4 million in sales beat. PODD stock tumbled....
Insulet Reports Full Year 2019 Revenue of $738.2 Million, an Increase of 31%, and Fourth Quarter 2019 Revenue of $209.4 Million, an Increase of 27% Year-Over-Year
Feb 25, 2020 @ 21:01
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2019....
Insulet to Present at Upcoming Investor Conferences
Feb 24, 2020 @ 13:38
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at four upcoming investor conferences (all times below are in Eastern Time):...